Friday 6 November 2026 Export ADMA’s income statement to Excel — free account

ADMA Biologics Inc

ADMA Healthcare Biotechnology

ADMA Biologics Inc’s revenue for fiscal 2025 (year ended December 2025) was $510.2 million, up 19.6% from fiscal 2024.

Revenue: +5.12%
EPS: +46.7%
Free cash flow: +1,709.5%
Total debt: +140.5%

Quarter to September 2026, against a year earlier

12.91 0.30 −2.27%

Follow ADMA

Alert me

Market cap: $3.0B
P/E: 16.7×
Fwd P/E: 14.0×
Dividend yield: —
F-score: 5/9
Altman Z: 19.98
Beneish M: −0.17
Dividend safety: n/a

Overview

ADMA Biologics Inc (ADMA) Price to free cash flow

Alert me on Price to free cash flow

As of 5 November 2026, ADMA Biologics Inc (ADMA) trades at a price to free cash flow of 24.5×. Over the past ten years it has ranged from 0.0× (December 2023) to 375× (March 2024); the current reading is higher than 81% of that period. That is in line with the Biotechnology industry median of 24.8× and above the Healthcare sector median of 21.1×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/ADMA/price-to-free-cash-flow" width="100%" height="360" style="border:0" loading="lazy" title="ADMA Biologics Inc price to free cash flow, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/ADMA/metrics/price-to-free-cash-flow">ADMA Biologics Inc (ADMA) price to free cash flow — stockrow.com</a></p>

Period	Price to free cash flow	Change
FY2025	158×	335.25%
FY2024	36.3×	(85.65%)
FY2023	253×	—
FY2022	0.0×	—
FY2021	0.0×	—
FY2020	0.0×	—
FY2019	0.0×	—
FY2018	0.0×	—
FY2017	0.0×	—
FY2016	0.0×	—

Period	Price to free cash flow	Change
Sep 2026	18.7×	13.53%
Jun 2026	16.4×	(13.02%)
Mar 2026	18.9×	(88.04%)
Dec 2025	158×	83.46%
43 more quarters	Free account

Against its own ten years

Low 0.0× High 375×

Ten-year median 0.0×

Current reading's percentile 81

Company	Price to free cash flow
PVLA Palvella Therapeutics, Inc. compare	n/m
PHVS Pharvaris N.V. compare	n/m
BHVN Biohaven Ltd. compare	n/m
VERA Vera Therapeutics, Inc. compare	n/m
CLDX Celldex Therapeutics, Inc. compare	n/m
IMNM Immunome, Inc. compare	n/m
AUPH Aurinia Pharmaceuticals Inc compare	12.2×
ADMA ADMA Biologics Inc	24.5×
VCEL Vericel Corporation compare	45.4×
Biotechnology industry median	24.8×
Healthcare sector median	21.1×
Market median	14.1×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

ADMA Biologics Inc (ADMA) Price to free cash flow

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on ADMA

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on ADMA

Stockrow Weekly